July 22, 2026 —
Affinia Therapeutics announced that the U.S. Food and Drug Administration has granted Orphan Drug designation to AFTX-201, an investigational AAV gene therapy for BAG3-associated dilated cardiomyopathy, or BAG3 DCM.
AFTX-201 is designed as a one-time intravenous genetic medicine intended to address the underlying genetic cause of BAG3 DCM. The therapy delivers a functional BAG3 transgene using Affinia’s proprietary rationally designed AAV capsid, which is engineered for efficient cardiac transduction.
According to Affinia, the capsid is designed to support cardiac delivery at doses that are 5- to 10-fold lower than those used in traditional gene therapies based on conventional capsids such as AAV9 or AAVrh74. The company describes AFTX-201 as a potential best-in-class investigational therapy for BAG3 DCM.
BAG3-associated DCM is caused by genetic mutations that reduce production of BAG3 protein in cardiomyocytes. Loss of BAG3 function can lead to early-onset progressive heart failure, impaired quality of life, and reduced survival despite current standard treatments.
Preclinical studies in an animal model of BAG3 DCM showed that AFTX-201 increased BAG3 protein levels in the heart, restored cardiac function, reversed structural abnormalities characteristic of the disease, and demonstrated a survival benefit.
AFTX-201 is currently being evaluated in the UPBEAT© clinical trial, a Phase 1/2 study enrolling adults with BAG3 DCM in the United States and Canada. The trial is evaluating the safety and efficacy of AFTX-201 in patients aged 18 to 55 who experience limitations in everyday physical activities due to heart failure.
The Orphan Drug designation follows the program’s recent Fast Track designation, further supporting Affinia’s regulatory path for AFTX-201. Orphan Drug designation is intended to encourage development of therapies for rare diseases affecting fewer than 200,000 people in the United States.
The designation provides potential development and commercial incentives, including tax credits for qualified clinical trial costs, exemption from FDA user fees for marketing applications, and the possibility of seven years of market exclusivity if the therapy is approved.
Based on published literature cited by Affinia, BAG3 mutation-associated DCM is estimated to account for 2.3% to 3.6% of dilated cardiomyopathy cases worldwide. No approved treatment currently addresses the underlying mechanism of BAG3 DCM.
The designation highlights growing momentum for cardiac AAV gene therapy, where improved capsid design, lower-dose delivery, and genetically defined patient populations may help advance durable treatment approaches for inherited cardiomyopathies.
